Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University, Japan.
J Atheroscler Thromb. 2009 Oct;16(5):539-45. doi: 10.5551/jat.281.
A novel device has been developed for measuring the cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. In this study, we evaluated the effect of pitavastatin on CAVI in type 2 diabetic patients.
Forty-five type 2 diabetes mellitus patients with low-density lipoprotein cholesterolemia were enrolled and treated with pitavastatin 2 mg/day for 12 months. Before and after pitavastatin administration, HbA1c, serum lipids, serum malondialdehyde-LDL (MDA-LDL), urinary 8-hydroxy- 2'-deoxyguanosine (8-OHdG) and CAVI were measured.
After pitavastatin treatment for 12 months, significant decreases in 8-OHdG, MDA-LDL and CAVI were observed. DeltaCAVI significantly correlated with DeltaMDA-LDL.
In type 2 diabetic patients, pitavastatin may have an oxidative stress-reducing effect, especially in a state of enhanced oxidative stress, and CAVI may be useful as a routine test for the diagnosis and therapeutic monitoring of atherosclerosis.
开发了一种新的设备来测量心血管踝动脉指数（CAVI）作为动脉僵硬度的指标。本研究评估了匹伐他汀对 2 型糖尿病患者 CAVI 的影响。
纳入 45 例 2 型糖尿病合并低密脂蛋白血症患者，给予匹伐他汀 2mg/天治疗 12 个月。在匹伐他汀给药前后测量 HbA1c、血脂、血清丙二醛-LDL（MDA-LDL）、尿 8-羟基-2'-脱氧鸟苷（8-OHdG）和 CAVI。
经过 12 个月的匹伐他汀治疗，8-OHdG、MDA-LDL 和 CAVI 显著降低。ΔCAVI 与 ΔMDA-LDL 显著相关。
在 2 型糖尿病患者中，匹伐他汀可能具有降低氧化应激的作用，尤其是在氧化应激增强的情况下，CAVI 可能作为动脉粥样硬化的诊断和治疗监测的常规检查有用。
